{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/natera-ntra/",
 "dataUrl": "https://clearank.com/stock/natera-ntra/data.json",
 "title": "NTRA Stock Forecast & Price Target (2026)",
 "description": "Is Natera (NTRA) a Buy or Sell today? Get the latest AI trade setup, key support levels and risk analysis after its Q2 beat. Updated daily.",
 "headline": "Natera, Inc. (NTRA)",
 "published": "2026-08-09T09:14:15+00:00",
 "modified": "2026-09-27T09:11:44.112+00:00",
 "generated": "2026-09-27T15:57:36.150Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "NTRA",
  "name": "Natera, Inc.",
  "type": "Common Stock",
  "exchange": "NASDAQ",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Diagnostics & Research",
  "country": "United States",
  "website": "https://www.natera.com"
 },
 "quote": {
  "price": 412.56,
  "previousClose": 408.79,
  "change": 3.77,
  "changePercent": 0.92,
  "open": 410,
  "high": 415.75,
  "low": 407.47501,
  "volume": 1612400,
  "averageVolume": 1932660,
  "marketCap": 59468118775,
  "fiftyTwoWeekHigh": 415.75,
  "fiftyTwoWeekLow": 157.425,
  "marketOpen": false,
  "asOf": "2026-09-27T09:11:43.000Z"
 },
 "statistics": {
  "pe": -271.4210510253906,
  "eps": -1.35,
  "dividendYield": 0,
  "beta": 1.534,
  "priceToSales": 21.967657,
  "priceToBook": 32.528584,
  "revenueTtm": 2707076096,
  "grossMargin": 0.6445552972434407,
  "returnOnEquity": -0.1254
 },
 "technicals": {
  "rsi": 87.7,
  "macd": 23.79,
  "sma50": 316.5,
  "sma200": 244.56,
  "rsiSignal": "Overbought",
  "trend": "Bullish",
  "pricePosition": "Bullish",
  "macdSignal": "Bullish",
  "rating": "Bullish"
 },
 "analysis": {
  "rating": "Sell",
  "score": 21,
  "consensus": "Sell",
  "fairValue": 350,
  "analystTarget": 350,
  "analystCount": 24,
  "wallStreetConsensus": "Buy",
  "generatedAt": "2026-09-27T09:11:43.000Z",
  "priceAtAnalysis": 412.56,
  "volatility": {
   "daily": 2.24,
   "risk": "standard"
  }
 },
 "tradePlan": {
  "bias": "Bearish",
  "conservativeEntry": 420.81,
  "aggressiveEntry": 412.56,
  "stopLoss": 437.73,
  "stopLossPercent": 4.02,
  "targets": [
   399.77,
   378.73,
   357.69
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 256.6,
    "base": 487.03,
    "upside90th": 924.38
   },
   {
    "year": 2028,
    "downside10th": 232.3,
    "base": 574.94,
    "upside90th": 1422.96
   },
   {
    "year": 2029,
    "downside10th": 223.7,
    "base": 678.72,
    "upside90th": 2059.27
   },
   {
    "year": 2030,
    "downside10th": 222.42,
    "base": 801.23,
    "upside90th": 2886.35
   },
   {
    "year": 2031,
    "downside10th": 225.7,
    "base": 945.86,
    "upside90th": 3963.82
   },
   {
    "year": 2032,
    "downside10th": 232.39,
    "base": 1116.59,
    "upside90th": 5365.07
   },
   {
    "year": 2033,
    "downside10th": 241.91,
    "base": 1318.14,
    "upside90th": 7182.27
   },
   {
    "year": 2034,
    "downside10th": 254.03,
    "base": 1556.06,
    "upside90th": 9531.63
   },
   {
    "year": 2035,
    "downside10th": 268.66,
    "base": 1836.94,
    "upside90th": 12559.8
   },
   {
    "year": 2036,
    "downside10th": 285.83,
    "base": 2168.52,
    "upside90th": 16451.73
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "NTRA Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$410.00",
    "Day Range": "$407.48 to $415.75",
    "Prev Close": "$408.79",
    "Volume": "1.61M",
    "52-Week Range": "$157.43 to $415.75",
    "Market Cap": "$59.47B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis On price-to-sales, the yardstick used here in place of P/E, NTRA trades at 21.97x, far above the sector average of 3.70x."
   ]
  },
  {
   "id": "financials",
   "title": "NTRA Financial Performance",
   "text": [
    "Analysis: In the last 4 quarters, NTRA beat estimates 2 times. However, the stock fell 1 times the next day. This suggests positive news is often \"priced in\" or investors are selling the news."
   ]
  },
  {
   "id": "analysis",
   "title": "NTRA Analysis",
   "text": [
    "Natera, Inc. (NTRA) exhibits strong bullish momentum, trading above its 50-day SMA ($316.50) and 200-day SMA ($244.56), as well as its 20-day EMA ($359.36). The Relative Strength Index (RSI) is at 87.7, indicating the stock is in overbought territory and may be due for a correction. The MACD is at 23.79, supporting the bullish trend but also suggesting momentum may be peaking. Volume has been below average recently, with the latest volume at 1.61 million compared to an average of 1.93 million. The current price action suggests strong buying interest has pushed the stock to new highs. Support can be found at the 50-day SMA of $316.50 and the 200-day SMA of $244.56. The high RSI suggests that traders may look to take profits, potentially leading to a short-term pullback. The stochastic oscillator is at 96.65, also confirming the overbought condition. Investors should watch for any signs of reversal or consolidation around current levels.",
    "Natera reported an EPS of $-0.47 for the quarter to June 2026, beating estimates by 11.32% and driving a 21.37% stock price increase, signaling positive operational execution.",
    "Insiders have sold $424.2 million in Natera stock with no reported purchases, indicating a heavy insider selling and potential lack of confidence in the current valuation.",
    "Analysts forecast current year revenue of $2.9 billion, a 26.00% year-over-year increase, highlighting strong market demand for Natera's diagnostic solutions.",
    "The RSI is at 87.7 and the stochastic oscillator is at 96.65, indicating the stock is significantly overbought and may be due for a price correction.",
    "Natera, Inc. (NTRA) is expected to continue its strong revenue growth trajectory, with current year sales projected to reach $2.9 billion, a 26.00% increase year-over-year. Analysts forecast a significant improvement in EPS for next year, moving from an estimated $-1.39 for the current year to $-0.10. The company's strong revenue growth and improving earnings estimates provide a foundation for potential future appreciation, despite current unprofitability and high valuation. However, the near-term outlook is clouded by the stock's overbought technical conditions and substantial insider selling. A correction is possible, especially if the company fails to meet the high growth expectations embedded in its current valuation. Key catalysts for upside would include continued strong earnings beats, positive clinical trial results, or strategic partnerships that further expand its market reach. Conversely, a failure to meet revenue targets, increased competition, or a shift in insider sentiment could lead to a significant downside."
   ],
   "lists": {
    "ProTips": [
     "Given the overbought RSI of 87.7 and significant insider selling, consider waiting for a pullback or consolidation before initiating new positions in Natera.",
     "Natera's price-to-sales ratio of 21.97 is substantially higher than the sector average, indicating a premium valuation that requires sustained high growth to justify.",
     "Monitor insider transaction trends closely; the current heavy selling pressure is a key risk factor that could precede a price correction."
    ]
   },
   "catalysts": [
    {
     "type": "Bullish",
     "title": "Strong EPS Beat in Q2 2026",
     "text": "Natera reported an EPS of $-0.47 for the quarter to June 2026, beating estimates by 11.32% and driving a 21.37% stock price increase, signaling positive operational execution.",
     "source": "Company Earnings Report"
    },
    {
     "type": "Bearish",
     "title": "Heavy Insider Selling Pressure",
     "text": "Insiders have sold $424.2 million in Natera stock with no reported purchases, indicating a heavy insider selling and potential lack of confidence in the current valuation.",
     "source": "Insider Transaction Data"
    },
    {
     "type": "Bullish",
     "title": "Projected Revenue Growth",
     "text": "Analysts forecast current year revenue of $2.9 billion, a 26.00% year-over-year increase, highlighting strong market demand for Natera's diagnostic solutions.",
     "source": "Analyst Estimates"
    },
    {
     "type": "Bearish",
     "title": "Overbought Technical Conditions",
     "text": "The RSI is at 87.7 and the stochastic oscillator is at 96.65, indicating the stock is significantly overbought and may be due for a price correction.",
     "source": "Technical Analysis Data"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "Natera, Inc. (NTRA) presents a mixed fundamental picture, with strong revenue growth but elevated valuation metrics. The company's revenue has grown by 37.7%, significantly outpacing the sector average of 8.1%. Its price-to-sales ratio stands at 21.97, which is considerably higher than the sector median of 3.7, indicating a premium valuation. The company's profitability metrics are currently negative, with a net profit margin of -7.11% and an operating margin of -10.29%. Return on equity is also negative at -12.54%. Despite the current unprofitability, analysts project Natera to move towards profitability, with estimated EPS for the current year at $-1.39 and for next year at $-0.10. Revenue estimates show continued growth, with current year sales projected at $2.9 billion, a 26.00% increase year-over-year. The company's debt-to-equity ratio is a healthy 0.13, below the sector average of 0.13, suggesting a manageable debt load. The high price-to-sales ratio, however, implies that the market has high expectations for future growth and profitability, which the company must meet to justify its current valuation.",
    "Natera, Inc. (NTRA) recently reported an EPS of $-0.47 for the quarter ending June 2026, beating the estimated $-0.53 by 11.32% and leading to a significant 21.37% price increase. This follows a pattern of mixed earnings performance, with a beat in the quarter to March 2026 (though the surprise percentage was negative) and a substantial beat in the quarter to March 2026 (EPS actual $0.36 vs estimate $-0.53). The company's ability to consistently beat or meet earnings expectations, particularly in recent quarters, is a positive sign for its operational execution, even as it navigates a period of negative EPS.",
    "Natera, Inc. (NTRA) faces significant risks stemming from its elevated valuation and heavy insider selling. The stock's price-to-sales ratio of 21.97 is substantially higher than the sector average, indicating a high degree of market expectation that could lead to sharp declines if growth falters. Also, the heavy insider selling from insider transactions, with $424.2 million in sales versus no purchases, suggests a lack of confidence from management regarding the current stock price. The company is also still operating at a net loss, with a negative profit margin of -7.11%, making it reliant on continued revenue growth and future profitability to sustain its valuation."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "59.47B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "N/A (Negative EPS)"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "-1.35"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "0.00%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "415.75"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "157.43"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bullish RSI Overbought SMA Cross Bullish Price vs SMA Bullish MACD Bullish Golden Cross in effect with the 50-day SMA ($316.50) above the 200-day SMA ($244.56), price action is firmly bullish above key moving averages, RSI at 87.7 indicates overbought conditions; consider caution for immediate entries."
   ],
   "facts": {
    "RSI": "Overbought",
    "SMA Cross": "Bullish",
    "Price vs SMA": "Bullish",
    "MACD": "Bullish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "87.70"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "23.79"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "316.50"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "244.56"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.45",
    "Correlation with Nasdaq 100 (QQQ)": "+0.44",
    "Correlation with Bitcoin (BTC)": "+0.07",
    "Correlation with Gold (XAU)": "+0.13"
   }
  },
  {
   "id": "trade-plans",
   "title": "NTRA Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Lower risk, wait for rally",
    "Higher risk, chasing the move",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (87.7) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$399.77",
    "TARGET 2": "$378.73",
    "TARGET 3": "$357.69",
    "STOP LOSS": "$437.73"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "+1.27%",
    "Average Feb return": "+1.70%",
    "Average Mar return": "-5.25%",
    "Average Apr return": "+5.56%",
    "Average May return": "+6.00%",
    "Average Jun return": "+15.31%",
    "Average Jul return": "-1.25%",
    "Average Aug return": "+19.35%",
    "Average Sep return": "-2.61%",
    "Average Oct return": "-2.40%",
    "Average Nov return": "+9.99%",
    "Average Dec return": "-2.73%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "2.24%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in NTRA in September 2016 would be worth about $384,492 today, compared with about $35,782 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in NTRA today could grow to about $52,562 by 2036 in the base case, with a bull case near $398,772 and a bear case around $6,928. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "NTRA Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $801 for NTRA by 2030 in the base case, from $413 today (1.9x over 4 years). The downside path ends near $222. These are outcomes of a Monte Carlo simulation run on NTRA's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using NTRA's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. NTRA is highly volatile, so its upside column reaches an extreme multiple; treat it as a statistical tail, not an expectation. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "NTRA simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$257",
        "$487",
        "$924"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$232",
        "$575",
        "$1,423"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$224",
        "$679",
        "$2,059"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$222",
        "$801",
        "$2,886"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$226",
        "$946",
        "$3,964"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$232",
        "$1,117",
        "$5,365"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$242",
        "$1,318",
        "$7,182"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$254",
        "$1,556",
        "$9,532"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$269",
        "$1,837",
        "$12,560"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$286",
        "$2,169",
        "$16,452"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "GILD Gilead Sciences, Inc. NASDAQ $150.93 +0.83%",
     "url": "https://clearank.com/stock/gilead-sciences-gild/"
    },
    {
     "text": "WST West Pharmaceutical Services Inc. NYSE $370.44 -0.85%",
     "url": "https://clearank.com/stock/wst-stock-analysis/"
    },
    {
     "text": "RXRX Recursion Pharmaceuticals, Inc. NASDAQ $3.74 -3.86%",
     "url": "https://clearank.com/stock/rxrx-stock-analysis/"
    },
    {
     "text": "TMO Thermo Fisher Scientific Inc. NYSE $675.00 -0.50%",
     "url": "https://clearank.com/stock/tmo-stock-analysis/"
    },
    {
     "text": "LEGN Legend Biotech Corporation NASDAQ $19.11 +0.26%",
     "url": "https://clearank.com/stock/legend-biotech-legn/"
    },
    {
     "text": "BDX Becton Dickinson and Co NYSE $183.82 +2.56%",
     "url": "https://clearank.com/stock/bdx-stock-analysis/"
    },
    {
     "text": "QDEL QuidelOrtho Corporation NASDAQ $10.94 +2.34%",
     "url": "https://clearank.com/stock/quidelortho-qdel/"
    },
    {
     "text": "GEHC GE HealthCare Technologies Inc. NASDAQ $66.63 +0.38%",
     "url": "https://clearank.com/stock/ge-healthcare-gehc/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Popular Comparisons",
   "links": [
    {
     "text": "Junior Gold Miners (GDXJ) vs Silver Miners (SIL) Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/gdxj-vs-sil/"
    },
    {
     "text": "QBTS vs QUBT Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/qbts-vs-qubt/"
    },
    {
     "text": "NOC vs LMT Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/noc-vs-lmt/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "NTRA Insider Trading Analysis",
   "facts": {
    "Bought": "None",
    "Sold": "$424.2M",
    "Insiders": "18",
    "Avg Transaction": "$2.3M"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in NTRA",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Mar 16, 2026",
       "cells": [
        "RABINOWITZ MATTHEW Officer and Director",
        "Sell",
        "200.0K",
        "$38.3M"
       ]
      },
      {
       "label": "Dec 13, 2023",
       "cells": [
        "HEALY JAMES I Director",
        "Sell",
        "644.0K",
        "$37.8M"
       ]
      },
      {
       "label": "Sep 15, 2026",
       "cells": [
        "RABINOWITZ MATTHEW Officer and Director",
        "Sell",
        "102.0K",
        "$34.8M"
       ]
      },
      {
       "label": "Nov 3, 2025",
       "cells": [
        "CHAPMAN STEVEN LEONARD Chief Executive Officer",
        "Sell",
        "160.7K",
        "$32.1M"
       ]
      },
      {
       "label": "Dec 13, 2024",
       "cells": [
        "RABINOWITZ MATTHEW Officer and Director",
        "Sell",
        "160.0K",
        "$26.5M"
       ]
      },
      {
       "label": "Jun 15, 2026",
       "cells": [
        "RABINOWITZ MATTHEW Officer and Director",
        "Sell",
        "100.0K",
        "$21.4M"
       ]
      },
      {
       "label": "Feb 3, 2026",
       "cells": [
        "CHAPMAN STEVEN LEONARD Chief Executive Officer",
        "Sell",
        "90.0K",
        "$20.8M"
       ]
      },
      {
       "label": "Nov 24, 2025",
       "cells": [
        "BOTHA ROELOF FREDERICK Director",
        "Sell",
        "75.0K",
        "$17.7M"
       ]
      },
      {
       "label": "Jan 21, 2026",
       "cells": [
        "CHAPMAN STEVEN LEONARD Chief Executive Officer",
        "Sell",
        "73.5K",
        "$17.3M"
       ]
      },
      {
       "label": "Jun 1, 2026",
       "cells": [
        "BOTHA ROELOF FREDERICK Director",
        "Sell",
        "78.0K",
        "$17.2M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Natera%2C+Inc.&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "What is Natera's stock price forecast for 2030?",
   "answer": "Based on Monte Carlo simulations, Natera's stock price forecast for 2030 shows a base case of $801.23, with a downside projection of $222.42 and an upside projection of $2886.35. These figures represent statistical outcomes and are not guaranteed price targets."
  },
  {
   "question": "Is Natera (NTRA) stock a buy right now?",
   "answer": "Natera (NTRA) is currently trading at $412.56. While analysts maintain a 'Buy' consensus with a median price target of $350, this implies a -15.2% downside. The stock is technically overbought, and significant insider selling presents a risk, suggesting caution is warranted."
  },
  {
   "question": "What are the key technical indicators for Natera stock?",
   "answer": "Natera's stock shows strong bullish momentum, trading above key moving averages. However, the RSI is at 87.7, indicating an overbought condition, and the stochastic oscillator is at 96.65, also confirming this. This suggests a potential for a short-term pullback."
  },
  {
   "question": "How does Natera's valuation compare to its sector peers?",
   "answer": "Natera's price-to-sales ratio is 21.97, significantly higher than the Healthcare sector average of 3.7. While the company exhibits strong revenue growth, its premium valuation suggests high market expectations for future performance."
  },
  {
   "question": "What is the sentiment from insider trading activity for Natera?",
   "answer": "Insider sentiment for Natera is currently bearish, with a heavy insider selling. Insiders have sold a total of $424.2 million in stock, with no reported purchases, indicating a lack of confidence at current price levels."
  },
  {
   "question": "What are the recent earnings results for Natera?",
   "answer": "Natera recently reported an EPS of $-0.47 for the quarter to June 2026, beating estimates by 11.32% and driving the stock price up by 21.37%. This follows a pattern of mixed but often surprising earnings performance."
  },
  {
   "question": "What is the consensus rating from Wall Street analysts for Natera?",
   "answer": "Wall Street analysts have a consensus rating of 'Buy' for Natera, with 5 Strong Buys, 16 Buys, and 3 Holds among 24 analysts. The overall Wall Street score is 77 out of 100."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "GILD",
    "name": "Gilead Sciences, Inc. NASDAQ",
    "price": "$150.93",
    "change": "+0.83%",
    "url": "https://clearank.com/stock/gilead-sciences-gild/"
   },
   {
    "ticker": "WST",
    "name": "West Pharmaceutical Services Inc. NYSE",
    "price": "$370.44",
    "change": "-0.85%",
    "url": "https://clearank.com/stock/wst-stock-analysis/"
   },
   {
    "ticker": "RXRX",
    "name": "Recursion Pharmaceuticals, Inc. NASDAQ",
    "price": "$3.74",
    "change": "-3.86%",
    "url": "https://clearank.com/stock/rxrx-stock-analysis/"
   },
   {
    "ticker": "TMO",
    "name": "Thermo Fisher Scientific Inc. NYSE",
    "price": "$675.00",
    "change": "-0.50%",
    "url": "https://clearank.com/stock/tmo-stock-analysis/"
   },
   {
    "ticker": "LEGN",
    "name": "Legend Biotech Corporation NASDAQ",
    "price": "$19.11",
    "change": "+0.26%",
    "url": "https://clearank.com/stock/legend-biotech-legn/"
   },
   {
    "ticker": "BDX",
    "name": "Becton Dickinson and Co NYSE",
    "price": "$183.82",
    "change": "+2.56%",
    "url": "https://clearank.com/stock/bdx-stock-analysis/"
   },
   {
    "ticker": "QDEL",
    "name": "QuidelOrtho Corporation NASDAQ",
    "price": "$10.94",
    "change": "+2.34%",
    "url": "https://clearank.com/stock/quidelortho-qdel/"
   },
   {
    "ticker": "GEHC",
    "name": "GE HealthCare Technologies Inc. NASDAQ",
    "price": "$66.63",
    "change": "+0.38%",
    "url": "https://clearank.com/stock/ge-healthcare-gehc/"
   }
  ],
  "comparisons": [
   {
    "ticker": "Junior Gold Miners (GDXJ) vs Silver Miners (SIL) Comparison",
    "name": "",
    "url": "https://clearank.com/compare/gdxj-vs-sil/"
   },
   {
    "ticker": "QBTS vs QUBT Comparison",
    "name": "",
    "url": "https://clearank.com/compare/qbts-vs-qubt/"
   },
   {
    "ticker": "NOC vs LMT Comparison",
    "name": "",
    "url": "https://clearank.com/compare/noc-vs-lmt/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "EIS",
    "text": "iShares MSCI Israel ETF",
    "url": "https://clearank.com/etf/eis-etf-analysis/"
   },
   {
    "ticker": "GWRE",
    "text": "Guidewire Software Inc.",
    "url": "https://clearank.com/stock/gwre-stock-analysis/"
   },
   {
    "ticker": "ROST",
    "text": "Ross Stores Inc.",
    "url": "https://clearank.com/stock/rost-stock-analysis/"
   },
   {
    "ticker": "LUGDF",
    "text": "Lundin Gold Inc",
    "url": "https://clearank.com/stock/lugdf-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "EIGEN/USD",
    "text": "↑ 8.20%",
    "url": "https://clearank.com/crypto/eigen-usd-crypto-analysis/"
   },
   {
    "ticker": "TWLO",
    "text": "↓ 7.96%",
    "url": "https://clearank.com/stock/twlo-stock-analysis/"
   },
   {
    "ticker": "CRDO",
    "text": "↑ 7.65%",
    "url": "https://clearank.com/stock/credo-crdo/"
   },
   {
    "ticker": "BLNE",
    "text": "↓ 7.40%",
    "url": "https://clearank.com/stock/blne-beeline-holdings/"
   },
   {
    "ticker": "GRT/USD",
    "text": "↑ 20.82%",
    "url": "https://clearank.com/crypto/the-graph-grt/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "DHR",
    "text": "Danaher",
    "url": "https://clearank.com/stock/dhr-stock-analysis/"
   },
   {
    "ticker": "IDXX",
    "text": "IDEXX",
    "url": "https://clearank.com/stock/idxx-stock-analysis/"
   },
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "IQV",
    "text": "IQVIA Holdings Inc.",
    "url": "https://clearank.com/stock/iqvia-iqv/"
   },
   {
    "ticker": "TMO",
    "text": "Thermo Fisher",
    "url": "https://clearank.com/stock/tmo-stock-analysis/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": "CleaRank Financial AI",
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@id": "https://clearank.com/#app"
     },
     "founder": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/08/ntra-natera.png",
     "url": "https://clearank.com/wp-content/uploads/2026/08/ntra-natera.png",
     "width": "1280",
     "height": "720",
     "caption": "Natera, Inc. (NTRA) stock price analysis chart for August 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/natera-ntra/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/natera-ntra/",
        "name": "Natera, Inc. (NTRA) Stock Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/natera-ntra/#webpage",
     "url": "https://clearank.com/stock/natera-ntra/",
     "name": "NTRA Stock Forecast & Price Target (2026)",
     "datePublished": "2026-08-09T09:14:15+00:00",
     "dateModified": "2026-09-27T09:11:44+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/08/ntra-natera.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/natera-ntra/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/shaundavidb/#person",
     "name": "Shaun David",
     "jobTitle": "Co-Founder",
     "url": "https://clearank.com/writer/shaundavidb/",
     "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg",
     "sameAs": [
      "https://www.linkedin.com/in/shaun-david-697b5817a/"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/natera-ntra/#richSnippet",
     "headline": "NTRA Stock Forecast & Price Target (2026)",
     "name": "NTRA Stock Forecast & Price Target (2026)",
     "description": "Is Natera (NTRA) a Buy or Sell today? Get the latest AI trade setup, key support levels and risk analysis after its Q2 beat. Updated daily.",
     "datePublished": "2026-08-09T09:14:15+00:00",
     "dateModified": "2026-09-27T09:11:44+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "about": {
      "@type": "Corporation",
      "name": "Natera, Inc.",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "NTRA"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NASDAQ"
       }
      ],
      "description": "Natera, Inc. is a molecular diagnostics company that develops and commercializes cell-free DNA and genetic testing services for clinical use. The company focuses on oncology, women’s health, and organ health, using proprietary molecular assays and bioinformatics to help detect and monitor genetic co",
      "tickerSymbol": "NTRA",
      "sameAs": "https://www.natera.com"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/natera-ntra/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/08/ntra-natera.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/natera-ntra/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "What is Natera's stock price forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on Monte Carlo simulations, Natera's stock price forecast for 2030 shows a base case of $801.23, with a downside projection of $222.42 and an upside projection of $2886.35. These figures represent statistical outcomes and are not guaranteed price targets."
     }
    },
    {
     "@type": "Question",
     "name": "Is Natera (NTRA) stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Natera (NTRA) is currently trading at $412.56. While analysts maintain a 'Buy' consensus with a median price target of $350, this implies a -15.2% downside. The stock is technically overbought, and significant insider selling presents a risk, suggesting caution is warranted."
     }
    },
    {
     "@type": "Question",
     "name": "What are the key technical indicators for Natera stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Natera's stock shows strong bullish momentum, trading above key moving averages. However, the RSI is at 87.7, indicating an overbought condition, and the stochastic oscillator is at 96.65, also confirming this. This suggests a potential for a short-term pullback."
     }
    },
    {
     "@type": "Question",
     "name": "How does Natera's valuation compare to its sector peers?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Natera's price-to-sales ratio is 21.97, significantly higher than the Healthcare sector average of 3.7. While the company exhibits strong revenue growth, its premium valuation suggests high market expectations for future performance."
     }
    },
    {
     "@type": "Question",
     "name": "What is the sentiment from insider trading activity for Natera?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Insider sentiment for Natera is currently bearish, with a heavy insider selling. Insiders have sold a total of $424.2 million in stock, with no reported purchases, indicating a lack of confidence at current price levels."
     }
    },
    {
     "@type": "Question",
     "name": "What are the recent earnings results for Natera?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Natera recently reported an EPS of $-0.47 for the quarter to June 2026, beating estimates by 11.32% and driving the stock price up by 21.37%. This follows a pattern of mixed but often surprising earnings performance."
     }
    },
    {
     "@type": "Question",
     "name": "What is the consensus rating from Wall Street analysts for Natera?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Wall Street analysts have a consensus rating of 'Buy' for Natera, with 5 Strong Buys, 16 Buys, and 3 Holds among 24 analysts. The overall Wall Street score is 77 out of 100."
     }
    }
   ]
  }
 ]
}